Nabriva Therapeutics PLC (NBRVF): Nabriva Therapeutics to Present at the 2...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	18
Posts	1646
Boards Moderated	0
Alias Born	06/26/2014

John-Knee

Re: None

Thursday, 07/30/2020 4:06:45 PM

Thursday, July 30, 2020 4:06:45 PM

Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
2020-07-30 04:01:12 PM ET (GlobeNewswire)

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12th, at 2:20p.m. ET.

The presentation will be webcast live and may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com. A replay of the webcast will be available for 90 days.

About Nabriva Therapeutics

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA(R) (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO(TM) (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

I use both Fundamental and Technical Analysis.
Opinions posted by me are just that, my opinion.
Buy/sell any type of financial security is the sole
decision of the individual. Make your own sound
judgement or consult a professional licensed
advisor.